Gastric cancer vaccine - OncoTherapy Science

Drug Profile

Gastric cancer vaccine - OncoTherapy Science

Alternative Names: OTSGC-A24

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OncoTherapy Science
  • Developer National University Hospital (Singapore); OncoTherapy Science
  • Class Cancer vaccines; Peptide aptamers; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gastric cancer

Most Recent Events

  • 07 Apr 2017 No recent reports of development identified - Phase-II for Gastric cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Singapore, South Korea, and Japan (SC)
  • 22 Mar 2016 The National University Hospital (Singapore) completes a phase I/II trial in Gastric cancer in Japan, South Korea and Singapore (NCT01227772,
  • 01 Jan 2015 Immunogenicity and adverse events data from a phase I/IIa trial in Gastric cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) presented at the ASCO Gastrointestinal Cancers Symposium 2015 (ASCO-GCS 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top